Met uw toestemming gebruiken we privacyvriendelijke, beperkte analyses om te begrijpen welke onderzoeksroutes werken. We gebruiken geen advertentietrackers of sessieopnamen. U kunt deze keuze wijzigen in Voorkeuren. Lees het Privacybeleid.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
CI — frequently asked questions
Is The Cigna Group overvalued?
In our latest published analysis dated 2026-10-22, CI looks meaningfully undervalued. The price recorded at analysis is USD 304 versus our fair value of USD 478; the high endpoint is presented separately as potential value of USD 825. That implies roughly 57.1% upside to fair value at that date.
Our latest published report, analyzed 2026-10-22, gives CI a fair value of USD 478 and a potential value of USD 825. The conclusion is triangulated across multiple valuation models and weighted by reliability for The Cigna Group's archetype; it is a dated research output, not a live price.
Should I buy CI now?
Our latest published rating for CI, analyzed 2026-10-22, is Strong Buy. The Cigna Group looks meaningfully undervalued at the analysis-date price of USD 304 versus fair value of USD 478; potential value is USD 825. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for CI?
The dedicated bear-case section in our report analyzed 2026-10-22 documents The Cigna Group's material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is CI's rating?
Our latest published rating for CI, analyzed 2026-10-22, is Strong Buy, with a published moat assessment of 7.5/10 (Narrow). It reflects our fair value of USD 478, the potential value of USD 825, and the price recorded at analysis (USD 304).
Engelse bron wordt weergegeven terwijl we vertalen
Dit rapport is nog niet vertaald. Vernieuw over een paar minuten zodra de vertaalwachtrij is bijgewerkt.
§1 SamenvattingEN
Antwoord in 30 secondenStrong Buy
Koers versus waarde
Koers
$304.37
Reële waarde
$478.08
Potentiële waarde
$825.00
Per
2026-10-21
Waarom het kan werken
The ongoing commercialization and volume scaling of interchangeable biosimilars and complex specialty therapies through Evernorth Specialty & Care Services represents Cigna's premier growth opportunity.
Wat onze visie zou veranderen
Termination, non-renewal, or severe fee clawbacks on the single pharmacy benefit client contract representing 19% ($52.2B) of FY2025 consolidated revenue.
The Cigna Group ($304.37) presents an asymmetric investment opportunity, trading at an attractive forward multiple against managed care peers. With Fair value assessed at $478.08, Cigna offers 57.1% implied return driven by Evernorth dominant specialty pharmacy volume, resilient commercial self-funded underwriting, and robust annual free cash generation deployed into share buybacks.
The Cigna Group operates from an advantaged structural position across the US healthcare landscape. Through Evernorth Health Services, Cigna administers pharmacy solutions for 118.2 million customers and dispenses critical therapies for complex conditions. Evernorth generated $234.95B in revenue in FY2025, providing immense procurement scale. In parallel, Cigna Healthcare administers medical coverage for 18.4 million members, predominantly through capital-light self-funded arrangements paired with over $8B in stop-loss premium.
Enterprise earnings are insulated from government-sponsored program volatility. Unlike peers exposed to Medicare Advantage rate cuts, Cigna concentrates on commercial employer plans and fee-based healthcare services. In Q2 2026, total revenues rose 7% to $71.7B and adjusted income from operations increased 6% to $2.1B ($7.78 per share), leading management to raise full-year 2026 adjusted EPSguidance to at least $30.45. Free cash flow reached $8.39B in FY2025, supporting $3.62B in share repurchases.5,6,7
At $304.37, Cigna trades at a steep valuation discount relative to peer multiples for CVS, ELV, and UNH. This market pricing overly discounts regulatory scrutiny on pharmacy benefit management, creating a favorable risk-reward skew toward Fair value of $478.08.4
Dominant Specialty Pharmacy Scale and Biosimilar Tailwinds
Evernorth generated $234.95B in FY2025 revenue and is accelerating adoption of interchangeable biosimilars, which provides margin expansion in specialty distribution.5,8
Exceptional Free Cash Flow Conversion and Capital Return
Substantial Valuation Discount to Managed Care Peers
Trading at 8.26x forward P/E against CVS at 11.10x, ELV at 14.87x, and UNH at 18.03x, the market heavily discounts regulatory risk, creating substantial multiple expansion upside toward mid fair value of $478.08.
Huisaanbeveling
Strong Buy. The Cigna Group trades at an attractive valuation relative to Fair value of $478.08, offering 57.1% upside backed by Evernorth specialty scale, transparent pricing transition, and high cash conversion.
Bedrijfsoverzicht
The Cigna Group is a global healthcare services corporation operating through two primary business divisions: Evernorth Health Services and Cigna Healthcare. Evernorth includes Pharmacy Benefit Services and Specialty and Care Services, delivering drug claim adjudication, home delivery, clinical specialty distribution, and care management across 118.2 million pharmacy customers. Evernorth generated $234.95B in FY2025 revenue, representing 85.5% of total enterprise revenue,.
Cigna Healthcare provides commercial insured and self-insured health plans, stop-loss underwriting, and international healthcare solutions serving 18.4 million medical members. Cigna Healthcare generated $47.41B in FY2025 revenue. Cigna focuses heavily on the commercial self-funded employer market, pairing administrative services with integrated specialty pharmacy and stop-loss products.
§2 BerenscenarioEN
A combined stress scenario models the compounding impact of an abrupt contract re-pricing on Cigna's largest pharmacy client (representing 19% of external revenues), alongside persistent high-single-digit medical inflation that lifts Cigna Healthcare MCR past 86.5%. Under this joint shock, consolidated EBIT margin compresses from 3.35% in FY2025 to below 2.50%. While Cigna's capital-light structure and strong operating cash flow of ~$9B ensure full debt service coverage on its $31.46B total debt, discretionary share repurchases would decelerate sharply from the $3.62B deployed in FY2025, dampening EPS growth.
Persistent medical cost inflation in high single digits lifts commercial MCR above 86.0%,.5
EPS growth decelerates significantly below the long-term target algorithm, and buyback capacity is reduced.
In the downside scenario, pricing concessions on major health plan contracts and heightened regulatory scrutiny restrict rebate retention across Evernorth Pharmacy Benefit Services. Simultaneously, persistent healthcare inflation across inpatient and outpatient care keeps Cigna Healthcare MCR elevated near the upper end of historical ranges, slowing cash flow compounding and keeping the valuation multiple depressed.
Hoe deze these kan breken
Loss or Re-pricing of Single 19% Revenue PBM Client
SEC Form 10-K footnote disclosures confirm that a single pharmacy benefit client accounted for approximately 19% ($52.2B) of total consolidated external revenues in FY2025, up from 16% in FY2024, housed entirely within Evernorth. Total pharmacy customers decreased 4% in 1H 2026 to 118.2M. A contract termination, loss to a competitor, or forced unbundling under FTC scrutiny would decimate Evernorth procurement scale and volume-based manufacturer rebates, driving an estimated 28.5% fair value impairment.8
FV impact
-2.2%
Revenue and EPS growth 5 points lower for five years
Trigger
Within 18 months
Vroege waarschuwingssignalen om te volgen
De vijf ontwikkelingen die onze beleggingsthese zouden verzwakken.
01
Customer Single Pharmacy Benefit Client Revenue Share
Client contract termination, loss to a competing PBM, or client defection following FTC antitrust unbundling scrutiny, impairing Evernorth procurement scale.
The Cigna Group possesses a narrow economic moat rooted in the immense operational scale of Evernorth Health Services and high switching costs across Cigna Healthcare's commercial employer client base. In FY2025, Evernorth generated $234.95B in revenue, accounting for 85.5% of consolidated revenues,. Operating alongside CVS Caremark and OptumRx in an oligopolistic pharmacy benefit market, Evernorth commands unmatched purchasing power with pharmaceutical manufacturers, capturing volume rebates and driving biosimilar adoption that lowers drug costs for plan sponsors.
Complementing its pharmacy scale, Cigna Healthcare serves 18.4 million medical members primarily through self-funded administrative services arrangements. By pairing ASO fee administration with stop-loss coverage generating over $8B in premiums, Cigna protects employers against catastrophic medical claims while maintaining minimal balance-sheet underwriting risk. Enterprise clients face substantial operational friction and employee disruption when attempting to unbundle these complex care management and pharmacy benefit workflows.
While regulatory inquiries into PBM pricing practices remain active, Cigna is insulating its moat by proactively deploying Evernorth Signature, a transparent cost-plus model with dynamic dispensing fees. Management anticipates Signature will yield margins near 4%, in line with legacy pharmacy products. This transition, combined with an ROIC of 10.16% against a 6.70% WACC, confirms the durability of Cigna's economic moat.
Economische winst
In FY2025, Cigna generated $9.20B in GAAP operating income on $274.90B in revenue,. Applying the 19.19% effective tax rate yields net operating profit after tax (NOPAT) of $7.43B. Evaluated against year-end invested capital of $73.18B, Cigna achieved an ROIC of 10.16%, comfortably exceeding its computed WACC of 6.70% by 346 basis points. This positive economic spread demonstrates that Cigna's scale and capital efficiency compound enterprise value above its cost of capital.2,6,7
7.5/ 10
Narrow
Sources of advantage
01Scale Advantage in Specialty Pharmacy and PBM Procurement — Evernorth Health Services generated $234.95B in FY2025 revenue, dispensing over 8 million specialty prescriptions annually and serving 118.2M pharmacy customers. This immense purchasing volume secures superior drug procurement discounts and manufacturer rebates that smaller rivals cannot replicate.Wide
02High Switching Costs in Self-Funded Commercial Health Plans — Cigna Healthcare administers medical coverage for 18.4M commercial and international customers. Multi-year administrative services only (ASO) contracts feature deeply integrated health intelligence, clinical data exchange, and pharmacy benefit coordination that generate renewal rates consistently above 95% in commercial employer segments.Wide
Bekende bedreigingen voor het concurrentievoordeel
Bedreiging
Ernst
Tijdlijn
Beperking
Federal and State PBM Regulatory Reform and Spread Pricing Bans
high
12-24 months
Scaling the transparent Evernorth Signature reimbursement model featuring cost-plus dynamic dispensing fees, targeting long-term segment operating margins of approximately 4%.5
The highlighted cell is Fair value when every assumption sits at its base level ($478.08). Each row and column shows what Fair value becomes when one assumption moves.
Evernorth Specialty & Care Services pre-tax income expands above 15% annually driven by rapid biosimilar uptake.5
Cigna Healthcare medical care ratio remains disciplined near the favorable end of guided ranges, supported by commercial pricing power.
Share repurchases retire 2.0% of diluted shares annually, driving EPS growth of 12-14%.5
Under the bull scenario, biosimilar adoption accelerates beyond management expectations, expanding specialty pharmacy margins. Commercial employer enrollment grows in Middle and Select markets, while transparent Evernorth Signature contracts scale rapidly with early adopters. Enterprise earnings compound at the upper end of management's 10-14% long-term target, driving valuation multiple expansion toward the high end of our fair value range ($825.00).5
Consolidated revenue grows at 4.0% to 4.5% annually across FY2026-FY2027 in line with consensus ($287.45B and $299.16B),.
§7 Beslissingsboom voor winstenEN
Overtroffen
Maintain Strong Buy; Reaffirm full target allocation, monitor biosimilar volume adoption curves across Specialty & Care Services, and audit conversion of operating cash flow into share repurchases.
Trigger: Consolidated FY2026 adjusted EPS exceeding $30.71 (above consensus high) with Evernorth pre-tax operating income topping $6.95B.1
An earnings beat driven by biosimilar volume adoption and commercial stop-loss underwriting margin expansion validates the core compounding thesis and supports management long-term double-digit EPS growth algorithm.
Conform
Maintain Strong Buy; Maintain target portfolio weighting and confirm that commercial medical care ratios remain disciplined within guided corridors.
Trigger: Consolidated FY2026 adjusted EPS between $30.45 and $30.55, matching guidance of at least $30.45 and consensus mean of $30.51.1,5
Meeting reaffirmed guidance confirms steady EPS compounding, supported by consistent share count retirement and resilient commercial employer underwriting.
Gemist
Downgrade the rating; Pause additional capital deployment, audit commercial underwriting risk retention, and evaluate client retention trends across pharmacy services.
Trigger: Consolidated FY2026 adjusted EPS missing lowered guidance thresholds with Cigna Healthcare medical care ratio deteriorating above target corridors.
A guidance reduction or margin deterioration in pharmacy benefit services indicates intensified pricing pressure, unrecovered medical inflation, or market share losses.
Winstkwaliteit
Cigna exhibits robust earnings quality underpinned by strong cash conversion. In FY2025, operating cash flow reached $9.60B and free cash flow stood at $8.39B, significantly exceeding GAAP net income of $5.96B (141% FCF-to-net-income conversion),,. The primary adjustments between GAAP net income of $6.29 per share and adjusted operating income of $7.78 per share in Q2 2026 consist of predictable non-cash intangible amortization ($1.12 per share) and strategic optimization costs ($0.20 per share). Operating accruals remain clean with minimal non-operating noise.6,7
Ontwikkeling van schattingen
Following the Q2 2026 earnings release and management's guidance increase to at least $30.45 per share, consensus earnings expectations have revised upward. Consensus FY2026 EPS rose from $30.41 pre-event to $30.51 currently, with 24 analysts contributing. FY2027 EPS consensus advanced from $33.48 to $33.49. Revenue estimates similarly strengthened, rising to $287.45B for FY2026 and $299.16B for FY2027,.1,5
Te volgen metrieken vóór publicatie
01
Metriek:
Specialty Generics and Biosimilar Penetration
HuidigManagement noted biosimilar adoption was recognized earlier than planned in 1H 2026 and remains a meaningful tailwind for the second half.
Waarom het ertoe doet
High-margin specialty generics and biosimilars expand Evernorth Specialty and Care pre-tax earnings, offsetting retail pharmacy margin normalization.
02
Metriek:
Single Pharmacy Benefit Client Contract Stability
HuidigFootnote disclosures confirm a single client represented 19% ($52.2B) of FY2025 external revenue, up from 16% in FY2024.
Cigna's cash flow profile is exceptionally strong, characterized by low capital reinvestment needs and high cash conversion. In FY2025, the company delivered $9.60B in operating cash flow and $8.39B in free cash flow on $5.96B of GAAP net income,,. Free cash flow conversion stood at 141% of net income and 87.4% of operating cash flow. For FY2026, management reaffirmed operating cash flow expectations of approximately $9B, alongside an Investor Day cumulative operating cash flow target of ~$50B through 2030. Working capital swings remain predictable due to commercial fee collection schedules and stop-loss claims settlement cycles.5,6,7
Cigna's ROIC demonstrates steady, durable capital efficiency. With invested capital at $73.18B and FY2025 operating income at $9.20B, after-tax operating profit of $7.43B produces an ROIC of 10.16%. The business model relies heavily on working capital velocity and customer contract scale rather than heavy property, plant, and equipment additions, ensuring returns on capital remain durable as biosimilar volumes scale.
Cigna's ROIC of 10.16% comfortably outpaces its computed WACC of 6.7034% by 346 basis points. This positive economic spread reflects Cigna's procurement power and disciplined commercial pricing, confirming that enterprise reinvestment continues to generate economic shareholder value.
Asset-Light Model Enables Premier Free Cash Flow Conversion
Cigna generated $8.39B in free cash flow on $1.21B in FY2025 ( of 0.44%),,.
Meest recente omzetUS$ 274,9 mld.Omzet-CAGR +23,9%
Operationele marge3,3%10 boekjaarperioden
Meest recente vrije kasstroomUS$ 8,4 mld.FY2025
NettoschuldUS$ 22,7 mld.FY2025
Uitsplitsing van de resultatenrekeningHoe bedrijfsschaal wordt omgezet in gerapporteerde winst.30 jun 2026
StockMarketAgent.AI
OmzetUS$ 71,7 mld.Kostprijs van de omzet−US$ 56,7 mld.BrutowinstUS$ 15 mld.Bedrijfskosten−US$ 12,3 mld.BedrijfsresultaatUS$ 2,7 mld.Niet-operationele posten en belastingen−US$ 1 mld.NettowinstUS$ 1,7 mld.
Financiële historische gegevens
Omzet
US$ 71.668.000.000
Kostprijs van de omzet
US$ 56.703.000.000
Brutowinst
US$ 14.965.000.000
Bedrijfskosten
US$ 12.289.000.000
Bedrijfsresultaat
US$ 2.676.000.000
Niet-operationele posten en belastingen
US$ -1.016.000.000
Nettowinst
US$ 1.660.000.000
Momentopname van de balansHoe de gerapporteerde activa in de geselecteerde periode worden aangehouden en gefinancierd.
The Cigna Group (CI) trades at 8.3x forward earnings against a peer median of 16.4x. Its EV/EBITDA of 8.3x compares with a peer median of 11.4x. The comparison uses 4 peers: Elevance Health Inc., CVS Health Corporation, Humana Inc. and UnitedHealth Group Incorporated, as of 2026-10-21.
§10 Sector & cyclusEN
Cyclusfase
Contraction
Industry benchmark data confirms low capital intensity across healthcare services, with an industry capex-to-revenue ratio of 0.90% (0.009) and capex-to-depreciation ratio of 0.81. Cigna's actual FY2025 capex was $1.21B on $274.90B revenue, representing a capex-to-revenue ratio of just 0.44%,.3,7
Bullencyclus
In a cyclical upswing, rapid penetration of lower-cost biosimilars expands specialty pharmacy operating margins, while commercial premium rate increases outpace outpatient utilization trends. Employer health plan sponsors expand self-funded coverage, lifting stop-loss premium volumes above $8B and accelerating enterprise adjusted EPS compounding toward the upper end of management's 10-14% long-term target.
Berencyclus
In a cyclical downturn, prolonged high-single-digit medical inflation outpaces commercial underwriting premium increases, driving medical care ratios above 86% and eroding risk margins. Concurrently, aggressive legislative bans on PBM spread pricing or employer client losses under antitrust unbundling scrutiny would compress pharmacy services margins and reduce fee-based earnings.
Seculaire trends
Trend
Impact
Notitie
Accelerated Biosimilar and Specialty Drug Penetration
positive
The commercialization of complex biologics and interchangeable biosimilars allows specialty pharmacies to substitute lower-cost therapies, generating higher gross margins while reducing client net costs. Evernorth's extensive clinical infrastructure positions Cigna to capture outsized market share in biosimilar distribution.
PBM Transparency Legislation and Cost-Plus Transition
neutral
Positionering
The Cigna Group is strategically positioned where healthcare costs concentrate: complex specialty therapies and commercial employer risk management. Unlike competitors heavily exposed to Medicare Advantage rate adjustments, Cigna derives over 85% of revenue from Evernorth Health Services, which benefits from volume-driven specialty pharmaceutical consumption. In commercial medical underwriting, Cigna's emphasis on self-funded ASO plans paired with stop-loss reinsurance minimizes underwriting balance-sheet volatility.8
§11 PositiebeheerEN
Positiegrootte
5-7%
High conviction is supported by Cigna's narrow economic moat in specialty pharmacy, premier cash flow generation ($8.39B FCF in FY2025), an 8.26x forward P/E multiple, and an 8.5% EPS compounding trajectory.3,6
Risico
Risk is managed through disciplined portfolio position sizing (5-7%), continuous monitoring of quarterly medical care ratios against the 83.7%-84.7% corridor, and tracking Evernorth Signature customer adoption ahead of 2027-2028 commercial scaling. The planned exit from the ACA Individual and Family Plans exchange business by January 1, 2027 removes underwriting volatility from the risk book.
Entree-tranches
Niveau
Actie
Waarom
Near $304.37
Initiate core position at target weight
Below $304.37
Add aggressively to reach maximum recommended weighting
Represents approximately 10.0x forward earnings on reaffirmed FY2026 EPSguidance of at least $30.45, providing extreme valuation support.
Pause position additions and audit specialty generic contribution margins.
§12 BeleggersperspectievenEN
Value and Fundamental Perspective
Buy
At 8.26x forward earnings, Cigna trades at a steep discount to CVS (11.10x), ELV (14.87x), and UNH (18.03x). The 57.07% implied upside to mid fair value ($478.08) provides significant upside potential.3,4
Growth and Compounder Perspective
Buy
Evernorth specialty pharmacy volume and expanding biosimilar distribution underpin an 8.5% EPS compounding trajectory and long-term 10-14% EPS growth targets, powered by ~$9B in annual operating cash flow.5
Defensive and Regulatory Perspective
Hold
Investors focused strictly on PBM legislative headline risk should hold existing allocations while monitoring FTC developments, noting that current depressed multiples already price in significant regulatory friction.
§14 EindaanbevelingEN
Actie
Sterk kopen
We assign a Strong Buy rating to The Cigna Group with Fair value of $478.08, representing 57.1% implied upside from $304.37,.3
Cigna combines dominant specialty pharmacy procurement scale, high free cash flow conversion ($8.39B in FY2025), and aggressive share repurchases, trading at an unwarranted discount of 8.26x forward earnings relative to peers.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
Analyst consensusData as of 2026-10-22 · Published 2026-10-22 · Provider-adjusted · cited for 5 figuresCited in Scenario's, Beslissingsboom voor winsten
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Legislative PBM Rebate Ban and Federal Margin Compression
Consolidated operating margin contracted steadily from 5.26% in FY2019 to 3.35% in FY2025,. In Q2 2026, Pharmacy Benefit Services pre-tax operating income fell 27% due to client pricing concessions and contract renewals. Bipartisan congressional legislation or FTC enforcement mandating 100% rebate pass-through and eliminating spread pricing would compress pharmacy services margins, pulling consolidated EBIT margin below 2.50% and driving an estimated 35.0% fair value impairment.7
FV impact
0%
Operating margin 3 points lower throughout
Trigger
Within 24 months
Persistent Medical Cost Inflation and Severe MLR Deterioration
Cigna Healthcare MCR increased to 84.5% in Q2 2026 from 83.2% in Q2 2025, approaching the upper boundary of full-year guidance of 83.7%-84.7%. Healthcare cost trends remain persistently elevated in high single digits across inpatient and outpatient care. If commercial underwriting pricing fails to outpace medical inflation and stop-loss claims surge, an MCR exceeding 86.5% would severely erode commercial earnings, driving an estimated 22.0% fair value impairment.5
FV impact
-5.4%
The analyst's bear scenario path and multiple as the base case
Trigger
Within 12 months
PBM Multiple De-Rating to Depressed Managed Care Multiples
Cigna trades at 8.26x forward P/E, discounted relative to peers CVS (11.10x), ELV (14.87x), and UNH (18.03x). If formal FTC antitrust litigation or legislative caps on PBM administrative fees materialize, multiple compression of 20% to below 7.0x would wipe out capital return gains, reducing fair value by an estimated 25.0%.3,4
Proprietary Clinical Care Integration and Stop-Loss Platform Breadth — Cigna couples fee-based self-insured employer solutions with stop-loss protection tracking over $8B in annualized premiums. This integrated underwriting and complex care coordination platform allows enterprise buyers to manage volatile high-cost specialty claims under unified administration.
Expanding multi-client specialty distribution, accelerating biosimilar and specialty generic penetration, and broadening middle-market commercial accounts,.5
Persistent Inpatient and Outpatient Medical Utilization Inflation
medium
6-18 months
Disciplined commercial renewal pricing to match forward medical cost trends, active stop-loss risk management, and the strategic exit from the volatile Individual and Family Plans ACA exchange business by January 1, 2027.5
Cigna Healthcare MCR tracks within full-year guidance of 83.7% to 84.7%.5
Diluted share count declines 1.5% to 1.8% annually via free-cash-flow-funded buybacks.7
The base case represents the modal expected trajectory, delivering an 8.5% EPS compounding path. Consensus FY2026 EPS of $30.51 and FY2027 EPS of $33.48 are met as Evernorth specialty volume offsets retail pharmacy pricing concessions. Re-rating to mid fair value of $478.08 reflects steady execution and capital return.1
Maintaining volume from Cigna's largest pharmacy client is critical to preserving procurement scale, rebate negotiations, and supply chain leverage.
03
Metriek:
Cigna Healthcare Medical Care Ratio (MCR)
HuidigReported at 84.5% in Q2 2026, tracking within full-year 2026 guidance of 83.7% to 84.7%.
Waarom het ertoe doet
Measures whether commercial premium rate increases sufficiently outpace persistent high-single-digit medical inflation across inpatient and outpatient care.
04
Metriek:
Evernorth Signature Model Rollout
HuidigTracking to scale the transparent cost-plus model in 2028, with Cigna Healthcare's insured book serving as early adopters in 2027, targeting ~4% margins.
Waarom het ertoe doet
Validates Cigna's ability to migrate commercial pharmacy relationships toward transparent fee-based models without sacrificing segment operating income.
05
Metriek:
Share Repurchase Execution and Share Count Retirement
HuidigRepurchased $3.62B of common stock in FY2025 and 0.9M shares for $250M through July 29, 2026.
Waarom het ertoe doet
Consistent share repurchases reduce diluted share count annually, serving as a primary pillar of enterprise EPS compounding.
Cigna adheres to a disciplined, shareholder-focused capital allocation framework. In FY2025, operating cash flow of $9.60B funded capital expenditures of $1.21B (12.6% of OCF),, leaving $8.39B in free cash flow. The company directed $3.62B to common share repurchases, driving a net reduction in diluted shares outstanding to 264.2M by October 2026. Long-term total debt of $31.46B represents a moderate 28.39% debt weight, well supported by annual operating cash flows guided at ~$9B for FY2026.
Low capital intensity allows over 100% of GAAP net income to be returned to shareholders via buybacks and dividends or deployed into digital care management platforms.
Evernorth Scale Diversifies Earnings Away from Medical Underwriting Risk
Evernorth produced $234.95B of Cigna's $274.90B FY2025 revenue (85.5%), while Cigna Healthcare contributed $47.41B,,.
Volume-driven specialty pharmacy cash flows shield enterprise operating income from medical loss ratio volatility that severely impacts pure-play health insurers.
Total debt of $31.46B represents a 28.39% debt weight against an $80.43B market capitalization,,.
With a pre-tax cost of debt of 5.80% and $9B+ in annual operating cash flow, debt service requirements are easily met, leaving ample balance sheet capacity.
Humana Inc.HUM
Koers / reële waarde
Reële waardeUS$ 264,45Report-date priceUS$ 388,36
Beoordelingsdatum
ConcurrentievoordeelNarrow
Beleggingsscorekaart59 / 100
UnitedHealth Group IncorporatedUNH
Koers / reële waarde
Reële waardeUS$ 448,25Report-date priceUS$ 376,9
Beoordelingsdatum
ConcurrentievoordeelNarrow
Beleggingsscorekaart63 / 100
Marge
CI
The Cigna Group
$80.4B
8.3x
0.3x
8.3x
16.8%
—
ELV
Elevance Health Inc.
$95.5B
14.9x
0.5x
10.7x
11.1%
4.6%
CVS
CVS Health Corporation
$121.2B
11.1x
0.3x
11.0x
6.2%
3.9%
HUM
Humana Inc.
$51.3B
25.0x
0.4x
11.8x
6.9%
3.5%
UNH
UnitedHealth Group Incorporated
$376.3B
18.0x
0.8x
14.7x
15.8%
5.8%
Bipartisan scrutiny and FTC inquiries are driving pharmacy benefit managers to adopt transparent, cost-plus reimbursement models. Cigna's rollout of Evernorth Signature proactively addresses transparency demands, securing commercial relationships under fee-based structures targeting stable ~4% margins.
Commercial Employer Shift Toward Self-Funded Health Plans
positive
Commercial employers continue shifting from guaranteed-cost risk policies to self-funded (ASO) structures to manage healthcare expenditure, driving demand for Cigna's integrated medical administration and stop-loss risk transfer.
Persistent Healthcare Utilization and Unit Cost Inflation
negative
Elevated medical cost inflation in high single digits across inpatient and outpatient care puts upward pressure on commercial medical care ratios when annual premium pricing adjustments lag utilization spikes.
